gemcitabine + pertuzumab + trastuzumab

This is a combination regimen consisting of gemcitabine, pertuzumab, and trastuzumab. Gemcitabine is a nucleoside analog used as a chemotherapeutic agent that inhibits DNA synthesis, leading to cell death. Pertuzumab and trastuzumab are both monoclonal antibodies targeting the human epidermal growth factor receptor 2 (HER2/ERBB2). Trastuzumab binds to subdomain IV of HER2, inhibiting downstream signaling and mediating antibody-dependent cellular cytotoxicity. Pertuzumab binds to subdomain II of HER2, preventing dimerization with other HER family receptors (notably HER3), thereby blocking ligand-activated signaling pathways involved in cell proliferation and survival. The combination is primarily investigated for use in patients with metastatic or advanced HER2-positive breast cancer who have previously received pertuzumab-based therapy[1][2][10]. This regimen has demonstrated activity and tolerability in phase 2 clinical trials for this population.

Brand names

PerjetaHerceptinGemzar

Other names

Gemcitabine, Trastuzumab, and Pertuzumab combinationGemcitabine + Trastuzumab + Pertuzumab